| Denosumab治疗绝经后骨质疏松症的临床研究进展 |
| |
| 作者姓名： | 张益嘉 罗丽平 刘衍志 |
| |
| 作者单位： | 1. 珠海市丽珠单抗生物技术有限公司,广东 珠海,519045;2. 广东天然药物研究与开发重点实验室,广东医科大学,广东 湛江524023 |
| |
| 摘 要： | 狄诺塞单抗(Denosumab)是首个上市的抗核因子κB受体活化因子配体(RANKL)治疗性单克隆抗体产品,主要用于治疗骨质疏松症和其他骨骼疾病.本文主要综述其近年国外治疗绝经后骨质疏松症的临床研究进展.
|
| 关 键 词： | Denosumab 核因子κB受体活化因子配体 绝经后骨质疏松症 临床研究 |
Clinical research progress of Denosumab for the treatment of postmenopausal osteoporosis |
| |
| Authors: | ZHANG Yiji LUO Liping and LIU Yanzhi |
| |
| Institution: | 1.Livzon Mabpharm Inc.,Zhuhai 519045,China;2.Guangdong Key Laboratory for R&D of Natural Drugs,Guangdong Medical University,Zhanjiang 524023,China,1.Livzon Mabpharm Inc.,Zhuhai 519045,China;2.Guangdong Key Laboratory for R&D of Natural Drugs,Guangdong Medical University,Zhanjiang 524023,China and 1.Livzon Mabpharm Inc.,Zhuhai 519045,China;2.Guangdong Key Laboratory for R&D of Natural Drugs,Guangdong Medical University,Zhanjiang 524023,China |
| |
| Abstract: | Denosumab is the first marketed product of anti-Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) monoclonal antibody for the treatment of osteoporosis and other bone diseases.The clinical research progress of Denosumab for the treatment of postmenopausal osteoporosis was reviewed in this article. |
| |
| Keywords: | Denosumab RANKL Postmenopausal osteoporosis Clinical study |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《》浏览原始摘要信息 |
| 点击此处可从《》下载免费的PDF全文 |
|
